
    
      Objective: The investigators aim to assess the efficacy of high dose of dexamethasone (20 mg
      / day 5 days, and 10 mg/day 5 days) versus low dose of dexamethasone (6 mg/day 10 days) in
      patients with respiratory failure by COVID-19.
    
  